ClinicalTrials.gg
Active, not recruitingNCT05024929Updated Nov 20, 2026

Targeted Therapy to Increase RAI Uptake in Metastatic DTC

An observational study in Papillary Thyroid Cancer, Pediatric Cancer and Differentiated Thyroid Cancer, sponsored by Children's Hospital of Philadelphia. Active, not recruiting at 8 sites in 2 countries. Open to participants aged 0 Years and older. Per ClinicalTrials.gov, last updated 2026-11-20.

Sponsored by Children's Hospital of Philadelphia · Observational

How we know

Updated Nov 20, 2026Now Active, not recruitingPrimary completion moved+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
32
Ages
0 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 76 studies in Thyroid Cancer, Papillary with a site in United States — 8 open to participants now, 18 under way, 1 of them phase 3. Thyroid Cancer, Papillary · United States.

Started
2021
with 5 others
Observational
9 of 76
3 open now
Primary completion
2027-07
later than 8 of 16 live
Registered
64th of 76
by date

Among the 76 studies in Thyroid Cancer, Papillary with a site in United States, this one is one of 6 that started in 2021, is one of 9 observational ones, reaches primary completion later than 8 of the 16 other live ones, and was the 64th registered.

Thyroid Cancer, Papillary

187 studies on the registry are indexed under Thyroid Cancer, Papillary; 50 are open to participants now.

Browse Thyroid Cancer, Papillary studies →

Open to participants now

8 of the 76 studies in Thyroid Cancer, Papillary with a site in United States are open now. Recruiting first, the newest first:

3 more — sign in →

All 8 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 31 Thyroid Cancer, Papillary studies recruiting now, 18 (58%) set no upper age limit and 8 (26%) stop at 75 or younger; 13 take children under 18; 3 take healthy volunteers.

This study: 0 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 76 studies in Thyroid Cancer, Papillary with a site in United States, or all of them as a file.
02

Study summary

Papillary thyroid cancer (PTC) is a common type of differentiated thyroid cancer (DTC) in children and represents the second most common cancer in adolescent females. Recently targeted drugs that block many of the genetic drivers of DTC have become available. While Investigators know that these drugs shrink DTC tumors in many cases, the impact on radioactive iodine (RAI) avidity has not been systematically studied.

Read the detailed description

This is an observational cohort study that will enroll patients with DTC metastatic to the lungs who will receive oncogene-specific targeted therapy as part of routine clinical care or a separate therapeutic clinical trial. After approximately 4 weeks of therapy, patients will have a whole body scan to determine the change in RAI-avidity of their tumor from baseline. Subsequent therapy will be at the discretion of the treating physician or according to the therapeutic trial on which the patient is enrolled.

03

Conditions studied

  • Papillary Thyroid Cancer
  • Pediatric Cancer
  • Differentiated Thyroid Cancer
04

Who can participate

Ages eligible
0 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

This study will enroll children and adolescents with differentiated thyroid cancer with pulmonary metastases who are planned to receive oncogene-specific targeted therapy.

Eligibility criteria

Inclusion Criteria (Prospective Cohort):

  1. Patients with a histologic diagnosis of differentiated thyroid cancer
  2. Presence of an neurotrophic tyrosine kinase receptors (NTRK)-fusion, RET-fusion, anaplastic lymphoma kinase (ALK)-fusion, BRAF V600 mutation, BRAF-fusion or other targetable alteration identified in a Clinical Laboratory Improvement Amendments/College of American Pathologists (CLIA/CAP) laboratory
  3. Anatomically evaluable disease on chest Computed tomography (CT) meeting oneo f the following criteria (obtained within 180 days of enrollment):

    1. multiple (10 or more) noncalcified solid pulmonary nodules visible on CT and/or
    2. enlarging, discrete pulmonary nodules visible on CT of any number consistent with disease
  4. Patients for whom systemic therapy with an oncogene-specific kinase inhibitor is planned from commercial supply or as part of a separate therapeutic clinical trial (that does not include data sharing with this protocol)/compassionate access protocol/single patient new drug (IND). Such agents include, but are not limited to:

    1. Larotrectinib, entrectinib, selitrectinib, and repotrectinib for NTRK fusions
    2. Selpercatinib and pralsetinib for RET fusions
    3. Crizotinib, lorlatinib, repotrectinib, and alectinib for ALK fusions
    4. Dabrafenib and/or trametinib for BRAF V600 mutations
    5. Oncogene-specific kinase inhibitors other than those specifically delineated above must be approved by the overall study PI prior to enrollment

Inclusion Criteria (Data Sharing Cohort):

1. Patients enrolled on other oncogene-specific targeted therapy trials who undergo whole body thyroid scan approximately 28 days after beginning targeted therapy and agree to data sharing as part of the consent process for that trial.

Exclusion Criteria (All Cohorts):

  1. No prior oncogene-specific targeted therapy allowed. However, patients may enroll within 4 weeks of starting oncogene-specific therapy if a pre-therapy WBS is available. Prior therapy with non-oncogene specific multi-thyrosine kinase inhibitors (such as sorafenib, lenvatinib, and/or cabozantanib) is allowed.
  2. Females who are pregnant or breastfeeding are excluded due to the potential risks of the RAI used in the WBS to the fetus/neonate.
  3. Patients who require sedation/general anesthesia to complete a WBS are excluded.
  4. U.S. Military Personnel are excluded due to the Children's Hospital of Philadelphia (CHOP) Institutional Review Board (IRB) requirements.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
32 participants (estimated)
Patient registry
No

Groups and cohorts

  • Prospective Cohort

    Patients with differentiated thyroid cancer for whom oncogene-specific targeted therapy is planned from commercial supply or as part of a separate therapeutic trial

    Procedure: Whole body scan

  • Data Sharing Cohort

    Patients with differentiated thyroid cancer enrolled on other oncogene-specific targeted therapy trials who undergo whole body thyroid scan approximately 28 days after beginning targeted therapy and agree to data sharing

Interventions

  • ProcedureWhole body scan

    Patients will receive oncogene-specific molecularly targeted therapy independently of this protocol either via commercial supply of an FDA approved agent, or as part of a separate therapeutic clinical trial/compassionate use protocol/single patient investigational new drug (IND). During screening, patients will undergo a baseline RAI-whole body scan (WBS) to assess RAI-avidity of their tumor per standard of care. Following approximately 28 days of targeted therapy, the WBS will be repeated to determine whether this therapy is associated with an increase in RAI-avidity of their tumor.

06

What researchers measure

Primary outcomes

  1. Proportion of patients with increased tumor RAI-avidity after receiving oncogene-specific, targeted therapy

    The primary outcome measure is to determine the proportion of patients with differentiated thyroid cancer metastatic to the lungs for whom oncogene-specific, targeted therapy increases tumor RAI-avidity.

    Time frame: up to 5 years

07

Study locations

8 sites
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Started Jul 2021 (actual). Primary completion is estimated for Jul 2027, 72 months after the start.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 20, 2026: primary completion Feb 2031 → Jul 2027 and completion Feb 2033 → Jul 2028.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Aug 23, 2021
First posted
Aug 27, 2021
StartActual
Jul 16, 2021
Primary completionEst.
Jul 2027was Feb 2031
CompletionEst.
Jul 2028was Feb 2033
Last update
Nov 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Active, not recruiting
changed Nov 20, 2026
Sites
1 site removed
Show 1 removed
  • Boston Children's Hospital · Boston, United States
Nov 20, 2026
Primary completion
Feb 1, 2031→Jul 2027
Nov 20, 2026
Study completion
Feb 1, 2033→Jul 2028
Nov 20, 2026
Show all 1 update
  1. Nov 20, 2026
    Recruiting→Active, not recruiting
    1 site removed
    Show 1 removed
    • Boston Children's Hospital · Boston, United States
    Primary completion Feb 1, 2031→Jul 2027
    Study completion Feb 1, 2033→Jul 2028
    + 2 other changes: verification date and contact details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05024929
Collaborators
United States Department of Defense
Responsible party
Sponsor
First posted
Aug 27, 2021
Start date
Jul 16, 2021
Primary completion
Jul 2027 (estimated)
Completion
Jul 2028 (estimated)
Last update
Nov 20, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion